• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026

    12/10/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email

    STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2025.

    Kewaunee Scientific Corporation (PRNewsFoto/Kewaunee Scientific Corporation)

    Fiscal Year 2026 Second Quarter Results:

    Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,453,000 compared to $3,931,000 for the prior year quarter, a decrease of 12.2%. Net earnings were $2,445,000 compared to net earnings of $3,008,000 for the prior year quarter. EBITDA1 for the quarter was $5,790,000 compared to $4,883,000 for the prior year quarter. Diluted earnings per share were $0.82 compared to diluted earnings per share of $1.01 in the prior year quarter.

    The Company's order backlog was $192.9 million on October 31, 2025, as compared to $184.4 million on October 31, 2024, and $214.6 million on April 30, 2025.

    Domestic Segment - Domestic sales for the quarter were $55,224,000, an increase of 51.7% from sales of $36,409,000 in the prior year quarter. Domestic segment net earnings were $3,597,000 compared to $4,524,000 in the prior year quarter. Domestic segment EBITDA was $6,712,000 compared to $6,838,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business, offset by the addition of Nu Aire, Inc. ("Nu Aire"), who had a strong quarter.

    International Segment - International sales for the quarter were $14,872,000, an increase of 31.0% from sales of $11,355,000 in the prior year quarter. International segment net earnings were $641,000 compared to $356,000 in the prior year quarter. International segment EBITDA was $860,000 compared to $592,000 for the prior year quarter. International sales increased when compared to the prior year period due to the continued delivery of large projects that were booked in prior periods, a trend that continues from the Company's first quarter fiscal year 2026 results.

    Corporate Segment – Corporate segment pre-tax net loss was $2,515,000 for the quarter, as compared to a pre-tax net loss of $2,444,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($1,782,000) compared to corporate segment EBITDA of ($2,547,000) for the prior year quarter. Corporate segment EBITDA improved year over year, largely driven by the inclusion of $1,540,000 of costs in the prior year period results directly related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024. In the current year period, the Company also incurred costs related to its strategic investment in its Corporate platform. These ongoing strategic investments in people, processes, and technology are intended to continue building out the Company's Corporate platform to support future anticipated growth.

    Total cash on hand on October 31, 2025, was $13,679,000, as compared to $17,164,000 on April 30, 2025. Working capital was $67,830,000, as compared to $59,965,000 at the end of the second quarter last year and $64,651,000 on April 30, 2025.

    The Company had short-term debt of $4,914,000 as of October 31, 2025, as compared to $4,773,000 on April 30, 2025. Long-term debt was $58,164,000 on October 31, 2025, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $26,205,000 of the long-term debt on October 31, 2025, and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $31,959,000 on October 31, 2025, as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio on October 31, 2025, was 0.88-to-1, as compared to 0.99-to-1 on April 30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on October 31, 2025, was 0.50-to-1, as compared to 0.57-to-1 on April 30, 2025.

    "As discussed in our prior earnings release, we expect volatility in project delivery timelines for the balance of the fiscal year and we saw that begin in quarter 2," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Our quoting and booking activity remain strong, which is reflected in our backlog that remains near record levels, specifically for our Domestic segment. Nu Aire had strong financial performance in the quarter, which helped to offset this volatility in the legacy business, which is more tied to the construction market. This dynamic illustrates our strategy, which we recently launched with the acquisition of Nu Aire, to diversify through well-targeted acquisitions. This strategy will also allow us to provide a broader set of laboratory solutions to the market."

    "While we still expect volatility in project delivery timing for the balance of this fiscal year," Hull continued, "we remain confident in the demand for our products and the strength of the markets we serve. Our current quoting activity gives us confidence that our backlog will remain strong through the end of the fiscal year, setting the company up for continuing success in fiscal 2027. Kewaunee's early repayment of the Seller Notes strengthens our balance sheet, positions us for further inorganic growth, and underscores our commitment to long-term value creation."

    ___________________

    1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

     

    EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation

    (Unaudited)

    ($ in thousands)

     

    Quarter Ended October 31, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                    4,524



    $                       356



    $                  (1,872)



    $                    3,008

    Add/(Less):

















    Interest Expense



    413



    19



    10



    442

    Interest Income



    —



    (133)



    (156)



    (289)

    Income Taxes



    1,241



    247



    (572)



    916

    Depreciation and Amortization



    660



    103



    43



    806

    EBITDA



    $                    6,838



    $                       592



    $                  (2,547)



    $                    4,883

    Professional Fees2



    —



    —



    1,540



    1,540

    Adjusted EBITDA



    $                    6,838



    $                       592



    $                  (1,007)



    $                    6,423



















    Quarter Ended October 31, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                    3,597



    $                       641



    $                  (1,793)



    $                    2,445

    Add/(Less):

















    Interest Expense



    311



    10



    740



    1,061

    Interest Income



    (2)



    (180)



    (29)



    (211)

    Income Taxes



    1,347



    290



    (722)



    915

    Depreciation and Amortization



    1,459



    99



    22



    1,580

    EBITDA



    $                    6,712



    $                       860



    $                  (1,782)



    $                    5,790

    Professional & Other Fees3



    —



    —



    350



    350

    Adjusted EBITDA



    $                    6,712



    $                       860



    $                  (1,432)



    $                    6,140



















    Year to Date October 31, 2024



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                    7,395



    $                       819



    $                  (3,013)



    $                    5,201

    Add/(Less):

















    Interest Expense



    854



    40



    20



    914

    Interest Income



    —



    (307)



    (329)



    (636)

    Income Taxes



    2,005



    526



    (1,423)



    1,108

    Depreciation and Amortization



    1,322



    210



    89



    1,621

    EBITDA



    $                  11,576



    $                    1,288



    $                  (4,656)



    $                    8,208

    Professional & Other Fees2



    —



    —



    2,270



    2,270

    Adjusted EBITDA



    $                  11,576



    $                    1,288



    $                  (2,386)



    $                  10,478



















    Year to Date October 31, 2025



    Domestic



    International



    Corporate



    Consolidated

    Net Earnings (Loss)



    $                    8,319



    $                    1,284



    $                  (4,065)



    $                    5,538

    Add/(Less):

















    Interest Expense



    624



    23



    1,472



    2,119

    Interest Income



    (2)



    (311)



    (39)



    (352)

    Income Taxes



    2,460



    724



    (1,508)



    1,676

    Depreciation and Amortization



    2,887



    195



    47



    3,129

    EBITDA



    $                  14,288



    $                    1,915



    $                  (4,093)



    $                  12,110

    Professional & Other Fees3



    —



    —



    574



    574

    Adjusted EBITDA



    $                  14,288



    $                    1,915



    $                  (3,519)



    $                  12,684

    ___________________

    2 Professional and other fees incurred during the three and six months ended October 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024

    3 Professional and other fees incurred during the three and six months ended October 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire

     

    Adjusted Consolidated Statement of Operations Reconciliation

    (Unaudited)

    ($ in thousands, except per share amounts)

     



    Three Months Ended October 31,



    As Reported

    2025



    Professional

    & Other Fees4



    Adjusted

    2025



    Adjusted

    2024

    Net sales

    $      70,096



    $              —



    $      70,096



    $      47,764

    Cost of products sold

    50,376



    —



    50,376



    33,812

    Gross profit

    19,720



    —



    19,720



    13,952

    Operating expenses

    15,613



    350



    15,263



    8,302

    Operating profit

    4,107



    350



    4,457



    5,650

    Other income, net

    407



    —



    407



    263

    Interest expense

    (1,061)



    —



    (1,061)



    (442)

    Profit before income taxes

    3,453



    350



    3,803



    5,471

    Income tax (benefit) expense

    915



    81



    996



    1,267

    Net earnings

    2,538



    269



    2,807



    4,204

    Less: Net earnings attributable to the non-controlling interest

    93



    —



    93



    7

    Net earnings attributable to Kewaunee Scientific Corporation

    $         2,445



    $            269



    $         2,714



    $         4,197

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $           0.85



    $           0.09



    $           0.95



    $           1.46

    Diluted

    $           0.82



    $           0.09



    $           0.91



    $           1.41





    Six Months Ended October 31,



    As Reported

    2025



    Professional

    & Other Fees4



    Adjusted

    2025



    Adjusted

    2024

    Net sales

    $    141,200



    $              —



    $    141,200



    $      96,157

    Cost of products sold

    100,550



    —



    100,550



    69,717

    Gross profit

    40,650



    —



    40,650



    26,440

    Operating expenses

    31,733



    574



    31,159



    17,485

    Operating profit

    8,917



    574



    9,491



    8,955

    Other income, net

    575



    —



    575



    590

    Interest expense

    (2,119)



    —



    (2,119)



    (914)

    Profit before income taxes

    7,373



    574



    7,947



    8,631

    Income tax (benefit) expense

    1,676



    130



    1,806



    1,626

    Net earnings

    5,697



    444



    6,141



    7,005

    Less: Net earnings attributable to the non-controlling interest

    159



    —



    159



    52

    Net earnings attributable to Kewaunee Scientific Corporation

    $         5,538



    $            444



    $         5,982



    $         6,953

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $           1.94



    $           0.16



    $           2.09



    $           2.43

    Diluted

    $           1.86



    $           0.15



    $           2.01



    $           2.34

    ___________________

    4 Professional and other fees incurred during the three and six months ended October 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire, including the estimated tax impact

    About Non-GAAP Measures 

    The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration of the Company's newly acquired subsidiary, Nu Aire, Inc., and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

    EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's integration of its newly acquired subsidiary,  Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to interest expense and interest income, income taxes, depreciation, amortization or the costs incurred related to the integration of Nu Aire, Inc., which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

    About Kewaunee Scientific

    Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. 

    Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

    Learn more at the companies' websites, located at https://www.kewaunee.com and https://www.nuaire.com/. 

    This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Kewaunee Scientific Corporation

    Condensed Consolidated Statements of Operations

    (Unaudited)

    ($ and shares in thousands, except per share amounts)

     



    Three Months Ended

    October 31,



    Six Months Ended

    October 31,



    2025



    2024



    2025



    2024

    Net sales

    $       70,096



    $       47,764



    $     141,200



    $       96,157

    Cost of products sold

    50,376



    33,812



    100,550



    69,717

    Gross profit

    19,720



    13,952



    40,650



    26,440

    Operating expenses

    15,613



    9,518



    31,733



    19,431

    Operating profit

    4,107



    4,434



    8,917



    7,009

    Other income, net

    407



    (61)



    575



    266

    Interest expense

    (1,061)



    (442)



    (2,119)



    (914)

    Profit before income taxes

    3,453



    3,931



    7,373



    6,361

    Income tax  expense

    915



    916



    1,676



    1,108

    Net earnings

    2,538



    3,015



    5,697



    5,253

    Less: Net earnings attributable to the non-controlling interest

    93



    7



    159



    52

    Net earnings attributable to Kewaunee Scientific Corporation

    $          2,445



    $          3,008



    $          5,538



    $          5,201

















    Net earnings per share attributable to Kewaunee Scientific Corporation stockholders















    Basic

    $            0.85



    $            1.05



    $            1.94



    $            1.82

    Diluted

    $            0.82



    $            1.01



    $            1.86



    $            1.75

    Weighted average number of common shares outstanding















    Basic

    2,866



    2,872



    2,859



    2,861

    Diluted

    2,990



    2,974



    2,977



    2,971

     

    Kewaunee Scientific Corporation

    Condensed Consolidated Balance Sheets

    ($ in thousands)

     



    October 31, 2025



    April 30, 2025



    (Unaudited)





    Assets







    Cash and cash equivalents

    $          12,594



    $           14,942

    Restricted cash

    1,085



    2,222

    Receivables, less allowances

    59,017



    62,384

    Inventories

    35,499



    32,849

    Prepaid expenses and other current assets

    5,445



    5,966

    Total Current Assets

    113,640



    118,363

    Net property, plant and equipment

    23,155



    23,174

    Right of use assets

    11,459



    12,965

    Deferred income taxes

    3,831



    3,994

    Net intangible assets

    17,063



    17,831

    Goodwill

    12,487



    12,487

    Other assets

    7,440



    5,840

    Total Assets

    $        189,075



    $         194,654









    Liabilities and Stockholders' Equity







    Short-term borrowings

    $            1,117



    $                986

    Current portion of lease obligations

    3,448



    3,371

    Current portion of financing liability

    827



    788

    Current portion of term loan

    2,903



    2,903

    Accounts payable

    22,660



    27,033

    Other current liabilities

    14,855



    18,631

    Total Current Liabilities

    45,810



    53,712

    Long-term portion of lease obligations

    7,592



    8,946

    Long-term portion of financing liability

    26,205



    26,632

    Long-term portion of seller note

    22,681



    23,537

    Long-term portion of term loan

    8,960



    10,412

    Other non-current liabilities

    6,110



    5,170

    Total Liabilities

    117,358



    128,409

    Kewaunee Scientific Corporation Equity

    69,852



    64,457

    Non-controlling interest

    1,865



    1,788

    Total Stockholders' Equity

    71,717



    66,245

    Total Liabilities and Stockholders' Equity

    $        189,075



    $         194,654

     

    Contact:

    Donald T. Gardner III



    704/871-3274

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-second-quarter-of-fiscal-year-2026-302638449.html

    SOURCE Kewaunee Scientific Corporation

    Get the next $KEQU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gardner Donald T. Iii sold $128,280 worth of shares (3,000 units at $42.76), decreasing direct ownership by 21% to 11,564 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    10/10/25 8:44:28 AM ET
    $KEQU
    Medical Specialities
    Industrials

    VP - Human Resources Phillips Elizabeth D sold $297,219 worth of shares (6,880 units at $43.20), decreasing direct ownership by 45% to 8,248 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    10/2/25 1:36:34 PM ET
    $KEQU
    Medical Specialities
    Industrials

    President, CEO Hull Thomas David Iii sold $43,090 worth of shares (1,000 units at $43.09), decreasing direct ownership by 3% to 38,719 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    10/2/25 9:16:06 AM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026

    STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2025. Fiscal Year 2026 Second Quarter Results: Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,453,000 compared to $3,931,000 for the prior year quarter, a decrease of 12.2%. Net earnings were $2,445,000 compared to net earnings of $3,008,000 for the prior year quarte

    12/10/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Announces Successful Debt Refinancing and Full Repayment of Seller Notes From the Company's Acquisition of Nu Aire, Inc.

    STATESVILLE, N.C., Dec. 4, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, today announced its successful debt refinancing and the full repayment of its Seller Notes. On December 4, 2025, Kewaunee Scientific Corporation (the "Company" or "Kewaunee") successfully repaid in full and ahead of schedule its Seller Notes, entered into November 1, 2024, in connection with the Company's acquisition of Nu Aire, Inc. ("Nu Aire"). The Seller No

    12/4/25 4:55:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2026

    STATESVILLE, N.C., Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's pr

    11/26/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    4/7/25 10:57:11 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/24/25 4:32:54 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/18/25 3:20:26 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    SEC Filings

    View All

    SEC Form 10-Q filed by Kewaunee Scientific Corporation

    10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/12/25 9:41:25 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/10/25 4:09:37 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/4/25 4:59:35 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    11/1/24 9:14:13 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 11:44:29 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 9:59:14 AM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Financials

    Live finance-specific insights

    View All

    Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

    STATESVILLE, N.C., June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025. Fiscal Year 2025 Fourth Quarter Results Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter. Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prio

    6/25/25 6:22:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

    STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

    3/12/25 4:16:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

    STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

    12/11/24 4:04:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Leadership Updates

    Live Leadership Updates

    View All

    Kewaunee Scientific Announces Appointment of J. Jette Campbell to Board of Directors

    STATESVILLE, N.C., Sept. 11, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, announces the appointment of J. Jette Campbell, CPA, to its Board of Directors, effective September 10, 2025. Campbell brings decades of experience guiding organizations through significant growth and transformation. Campbell's impressive career spans leadership roles at global companies such as PepsiCo, Frito-Lay, and Griffin LLC, a DuPont venture. He also

    9/11/25 4:03:00 PM ET
    $KEQU
    Medical Specialities
    Industrials